

Market Announcement

23 June 2026

Imagion Biosystems Limited (ASX: IBX) – Trading Halt

Trading in the securities of Imagion Biosystems Limited ('IBX') will be halted at the request of IBX, pending the release of an announcement by IBX.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Thursday, 25 June 2026; or
- the release of the announcement to the market.

IBX's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

23 June 2026

ASX Compliance Pty Limited
Level 4, North Tower,
525 Collins Street,
Melbourne, VIC 3000

By email only: ListingComplianceMelbourne@asx.com.au

REQUEST FOR TRADING HALT

Imagion Biosystems Limited (ASX: IBX) (the Company) requests an immediate halt to the trading of the Company's securities quoted on the Australian Securities Exchange (ASX) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending the release of information by the Company to the market relating to a Capital Raise ("purpose").

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make a material announcement to the market in relation to the stated purpose above.
2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on 25 June 2026, or when the announcement regarding the stated purpose is released to the market.
3. The Company expects to make the announcement to the market before the commencement of normal trading on Thursday 25 June 2026.
4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

Yours sincerely

Melanie Leydin
Director and Company Secretary